Since finishing medical school nearly 40 years ago, I’ve witnessed American scientists develop hundreds of lifesaving medicines that once seemed unimaginable.
While leading the National Heart, Lung, and Blood Institute at the National Institutes of Health, I saw scientists pioneer novel ways to treat rare and serious blood disorders in children.
During my tenure as president of Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, researchers have cured hepatitis C, a once-fatal liver disease that killed nearly 20,000 Americans annually as recently as 2014 and with new biologic therapies, have harnessed the power of terminal cancer patients’ own immune systems to provide new hope.
These cutting-edge medicines weren’t developed overnight. They required decades of research, hundreds of millions of dollars in seed funding, and a policy environment that fosters innovation. Unfortunately, our innovation ecosystem is now under assault.
It’s important for the American public to understand how drug development works — and how the next generation will suffer if we don’t provide scientists the resources required to enable continued innovation and discovery.
Basic scientific research, which is often subsidized by the federal government through the National Institutes for Health, is absolutely critical to biomedical innovation. During my time leading the NIH’s National Heart, Lung, and Blood Institute — which allocates about $3 billion in research grants each year — our team made great progress in better understanding how to treat and diagnose chronic diseases.
But government labs don’t turn promising insights into actual treatments. Often, it’s the small, venture-backed biomedical companies, increasingly in collaboration with the nation’s top academic medical centers, that do.
These firms translate basic research into applied science by identifying promising drug compounds and shepherding them through years of preclinical testing, human trials, and regulatory hurdles. These companies often partner with bigger firms once success is in sight.
But the process is rife with failure. Consider cancer drugs. Between 1998 and 2014, 177 potential lung cancer drugs entered clinical trials — yet only 10 were approved. During that same period, 96 potential drugs for melanoma failed, while only seven succeeded.
Because of this high failure rate, drug development is incredibly risky and expensive. Those who embrace the challenge do so because of a strong and predictable system that provides limited protections for the few successful medicines coming to market.
Investors in early-stage research firms accept these risks because they know the revenue from just one successful drug can pay for every failure and still generate a return. “Profit” has become a dirty word, but the market-based system we have is the main reason our country leads the world in drug innovation. Two-thirds of the new medicines released worldwide in the last decade came from the United States.
Now, our innovation ecosystem is being threatened. In Congress, some lawmakers want to import foreign price controls. Others want to introduce price controls in Medicare. Still others want to allow the federal government to set prices on any medicine whose origin lies in government-funded research.
Though doubtlessly well-intentioned, these policy changes could eliminate the financial incentives that allow research scientists to explore new treatments.
Policymakers and American citizens alike need to understand that government labs don’t develop drugs. Nor should we want them to. Congress sets the NIH’s budget and instructs the agency on how to spend that money. Tasking the NIH with drug discovery would politicize the research process. It’d enable a handful of government officials to decide which experimental treatments get funding — and which ones die in the lab.
I know first-hand that scientists working at federally funded labs are brilliant, but it’s neither their job nor their goal to create new medicines.
Patients are better off when the government allocates its limited resources towards basic scientific research, which often lacks an immediate application and thus would struggle to attract funding. This division of labor allows private companies to take on the risky, laborious, and hugely expensive drug development process.
If we want American firms to continue producing lifesaving treatments, we need to protect them.
Elizabeth G. Nabel, MD, is president of Brigham Health and its Brigham and Women’s Hospital. A cardiologist, she is a professor of medicine at Harvard Medical School and former Director of the National Heart, Lung and Blood Institute of the National Institutes of Health. Dr. Elizabeth Nabel’s husband, Dr. Gary Nabel, serves as CSO for Sanofi.